Hostile Takeover Defenses: The Interview Guide to Poison Pills, White Knights and More

You're in a superday, things are going well, and then the interviewer leans back and asks: "Walk me through how a company defends against a hostile takeover."

That's an M&A question, and it shows up a lot, especially for M&A groups and anyone who has put "interested in M&A" on their resume. This guide covers the main defenses, how they work (with real numbers), and how to talk about them in an interview.

First, What Makes a Takeover "Hostile"?

A takeover is hostile when the acquirer goes after a company whose board doesn't want to be bought. The acquirer skips the friendly negotiation, or tries it and gets rejected, then goes around management.

There are two main ways to do that:

• Tender offer: the acquirer goes directly to shareholders and offers to buy their shares, usually at a premium to the current price.
• Proxy fight: the acquirer asks shareholders to vote out the current board and elect directors who will approve the deal.

Many hostile bids start with a bear hug. That's a public letter to the board with an offer so attractive that rejecting it puts pressure on directors to explain themselves to shareholders.

Every defense below is designed to block one or both of these routes.

The Two Buckets: Preventive vs. Reactive

Interviewers love a structured answer. The easiest way to organize these defenses is by timing:

• Preventive defenses are put in place before any bidder shows up.
• Reactive defenses are deployed once a hostile bid is on the table.

Lead with this split and you'll immediately sound organized.

Preventive Defenses

Poison Pill (Shareholder Rights Plan)

This is the most famous one, and the one you absolutely need to understand. It was developed by lawyer Martin Lipton in the early 1980s, and the Delaware Supreme Court upheld it in Moran v. Household International (1985).

How it works: the company issues rights to all shareholders. If anyone acquires more than a set threshold of the stock (often somewhere in the 10% to 20% range), the rights "trigger." Every shareholder except the acquirer can then buy new shares at a steep discount.

The result: the acquirer's stake gets massively diluted, and buying the company through the open market becomes extremely expensive.

There are two flavors:

• Flip-in: shareholders buy discounted shares of the target. This is the common version.
• Flip-over: if the target is merged into the acquirer, shareholders can buy discounted shares of the acquirer.

Poison Pill: The Math

Let's run a simplified example.

Target company before the pill triggers:

• 100 million shares outstanding
• Share price: $20
• Market cap: $2.0 billion
• Pill threshold: 15%

A hostile bidder buys 15 million shares (15%), crossing the threshold. Their stake is worth 15M × $20 = $300 million.

Now the pill triggers. Assume each of the other 85 million shares gets a right to buy one new share at $10 (half price).

After the pill:

• New shares issued: 85 million
• Cash raised: 85M × $10 = $850 million
• Total shares: 100M + 85M = 185 million
• Total equity value: $2.0B + $0.85B = $2.85 billion
• New share price: $2.85B ÷ 185M = ~$15.41

What happened to the bidder?

• Ownership drops from 15% to 15M ÷ 185M = ~8.1%
• Stake value drops to 15M × $15.41 = ~$231 million
• That's a loss of roughly $69 million, or about 23%, overnight

And everyone else? Their 85 million shares lost value too, but they got 85 million new shares at a bargain. They come out fine. The bidder eats the pain alone.

That's why pills almost never actually trigger. Their real power is deterrence: they force the bidder to negotiate with the board instead of going around it.

Real example: in April 2022, Twitter's board adopted a one-year rights plan with a 15% threshold after Elon Musk disclosed a large stake and made an unsolicited offer. Twitter ultimately agreed to a deal, which shows the point: a pill doesn't make a company unbuyable. It pushes the bidder into a negotiation with the board.

Staggered (Classified) Board

Instead of electing all directors every year, the board is split into classes (typically three), and only one class is up for election each year.

Why it matters: a bidder running a proxy fight can only replace about a third of the board per annual meeting. Getting a majority takes two annual meetings, so you're looking at well over a year of fighting.

The killer combo: a poison pill plus a staggered board. The pill blocks the tender offer route. The natural workaround is a proxy fight to elect a new board that removes the pill. The staggered board makes that workaround painfully slow. Mention this combination in an interview and you'll stand out.

Supermajority Voting Provisions

The company's charter requires a very high approval threshold, like two-thirds or more of shareholders instead of a simple majority, to approve a merger or amend key provisions.

If insiders and friendly holders control a meaningful block, a supermajority rule can make a deal nearly impossible without their support.

Dual-Class Share Structure

The company issues different share classes with different voting rights. Founders or insiders hold shares with far more votes per share, while public investors get shares with fewer votes or none.

Alphabet and Meta are well-known examples. Their founders hold super-voting stock, so even a bidder that bought a huge chunk of the publicly traded shares couldn't take control. This is arguably the strongest defense on the list, because control simply isn't for sale without the insiders.

Golden Parachutes

These are large payouts to executives if they lose their jobs after a change of control.

Be careful here: golden parachutes raise the cost of a takeover somewhat, but they're usually small relative to deal size. They're better described as a way to keep management from fighting a deal that's good for shareholders just to save their own jobs. If an interviewer pushes, that nuance earns you points.

State Anti-Takeover Laws

Many companies are incorporated in Delaware, and Section 203 of Delaware's corporate law matters here. If someone acquires 15% or more of a company's stock without board approval, they generally can't complete a business combination with that company for three years, unless certain exceptions apply.

Reactive Defenses

White Knight

The target finds a friendlier acquirer and agrees to sell to them instead. The company still gets sold, but on terms the board prefers. That could mean a better price, a better cultural fit, or more job security for employees.

White Squire

A softer version of the white knight. Instead of selling the whole company, the target sells a significant minority stake to a friendly investor who will vote against the hostile bid. The company stays independent, with a powerful ally in its corner.

Pac-Man Defense

The target turns around and makes a bid for the acquirer. It's rare and requires the target to have serious financial firepower.

The classic case is the 1982 battle between Bendix and Martin Marietta: Bendix bid for Martin Marietta, and Martin Marietta responded by bidding for Bendix.

Crown Jewel Defense

The target sells, or agrees to sell, its most valuable asset or division to a third party. If the bidder mainly wanted that asset, the company suddenly becomes much less attractive.

The obvious risk: you might be destroying shareholder value to stay independent.

Leveraged Recapitalization

The target takes on a large amount of debt and uses it to pay a big special dividend or buy back shares. This does a few things at once:

• It hands shareholders value directly, which competes with the bidder's premium
• The heavy debt load makes the company less attractive to acquire, especially for a bidder planning to use leverage
• Buybacks can increase insiders' percentage ownership

Scorched Earth

The broad term for making the company deliberately less valuable or attractive, such as taking on huge liabilities or selling key assets. It's the "if I can't have it, no one can" approach, and boards rarely go this far because it can hurt the very shareholders they're supposed to protect.

Litigation

The target sues, arguing the deal violates antitrust law, securities rules or disclosure requirements. Even a weak lawsuit can buy time to find a white knight or negotiate a higher price.

The Legal Guardrails You Should Know

Boards can't just do anything to stop a deal. In Delaware, two cases come up constantly:

• Unocal (1985): defensive measures must be a reasonable response to a real threat. A board can't use defenses just to entrench itself.
• Revlon (1986): once a company is clearly being sold, the board's job shifts to getting the best price for shareholders. At that point, it can't favor one bidder over another for reasons that don't serve shareholders.

You don't need to be a lawyer, but knowing these names shows you understand that defenses operate within limits.

How to Answer This in an Interview

Here's a tight answer you can adapt:

"Takeover defenses fall into two buckets. Preventive defenses are set up before a bid: the poison pill, which dilutes a hostile acquirer once they cross an ownership threshold, staggered boards, supermajority voting, and dual-class shares. Reactive defenses come after a bid: finding a white knight, selling a stake to a white squire, the Pac-Man defense, selling crown jewel assets, or doing a leveraged recap. The most effective combination is usually a poison pill plus a staggered board, because the pill blocks a tender offer and the staggered board slows down a proxy fight to remove it. In practice, most defenses don't stop a deal outright. They give the board leverage to negotiate a higher price."

That last sentence is the insight interviewers want to hear.

Likely Follow-Up Questions

• "Are takeover defenses good for shareholders?" It depends. They can help the board extract a higher price, but they can also entrench management and block value-creating deals. Showing you see both sides is the right move.
• "Why have many companies dropped their poison pills and staggered boards?" Institutional investors and proxy advisors have pushed back on them as entrenchment tools. Companies can still adopt a pill quickly when a threat appears, so a standing pill isn't strictly necessary.
• "How would a bidder get around a poison pill?" Run a proxy fight to replace the board with directors who will redeem the pill, or make an offer attractive enough that shareholder pressure forces the board to negotiate.

The Bottom Line

Don't just memorize a list of colorful names. Understand what each defense blocks (the tender offer or the proxy fight) and why most defenses are really negotiating tools.

Learn the poison pill math, know the pill plus staggered board combo, and organize your answer into preventive and reactive. Do that, and this question goes from intimidating to one of your strongest moments in the interview.